HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by He, H. Articles by Morel, P. A. Search for Related Content PubMed PubMed Citation Articles by He, H. Articles by Morel, P. A. Agricola Articles by He, H. Articles by Morel, P. A.

T cell proliferative responses to five human cytomegalovirus proteins in healthy seropositive individuals: implications for vaccine development

¹ Departments of Medicine and Molecular Genetics and Biochemistry, University of Pittsburgh, Pittsburgh Cancer Institute, Pittsburgh, PA 15213
and² Department of Pathology, University of Pittsburgh, School of Medicine, Pittsburgh, PA 15261, USA

Cell-mediated immunity plays an important role in the host response against human cytomegalovirus (HCMV) infection. For the development of HCMV subunit vaccines it is essential to identify which HCMV proteins can induce protective immune responses in humans. We have studied the T cell proliferative responses to five HCMV proteins (IE1, IE2, pp71, gpUL18 and gB). These five proteins were produced using the maltose-binding protein (MBP) fusion protein system. T cell proliferative responses in 23 seropositive and six seronegative individuals were evaluated. None of the six seronegative individuals showed significant responses to any of the proteins. Of the 23 seropositive individuals, five responded to all five proteins, 14 responded to between one and four proteins and four responded to none of the proteins. The most commonly recognized proteins were gB (17/23, 74%) and IE2 (16/23, 70%). pp71 and IE1 were recognized by 10 of 23 (43%) individuals. Nine of 22 (41%) individuals tested responded to gpUL18, providing evidence that this protein is produced during infection. Our data indicate that a subunit vaccine composed of gB alone may not be sufficient to induce protective immunity in all individuals. The combination of two or three proteins may be more efficient as a potential vaccine.

^* Author for correspondence. Present address: Pittsburgh Cancer Institute, Biomedical Science Tower W1057, 200 Lothrop Street, Pittsburgh, PA 15213-2582, USA. Fax +1 412 624 7736. e-mail morel@novelll.dept-med.pitt.edu

Received 4 August 1994; accepted 31 January 1995.

This article has been cited by other articles:

				C. S. Wagner, L. Walther-Jallow, E. Buentke, H.-G. Ljunggren, A. Achour, and B. J. Chambers Human cytomegalovirus-derived protein UL18 alters the phenotype and function of monocyte-derived dendritic cells J. Leukoc. Biol., January 1, 2008; 83(1): 56 - 63. [Abstract] [Full Text] [PDF]

				C. S. Wagner, H.-G. Ljunggren, and A. Achour Immune Modulation by the Human Cytomegalovirus-Encoded Molecule UL18, a Mystery Yet to Be Solved J. Immunol., January 1, 2008; 180(1): 19 - 24. [Abstract] [Full Text] [PDF]

				E. Le Roy, M. Baron, W. Faigle, D. Clement, D. M. Lewinsohn, D. N. Streblow, J. A. Nelson, S. Amigorena, and J.-L. Davignon Infection of APC by Human Cytomegalovirus Controlled Through Recognition of Endogenous Nuclear Immediate Early Protein 1 by Specific CD4+ T Lymphocytes J. Immunol., August 1, 2002; 169(3): 1293 - 1301. [Abstract] [Full Text] [PDF]